A post hoc analysis of the DEN-301 placebo arm followed 30,620.6 person-years, identifying 560 virologically confirmed dengue cases among 9,698 febrile illnesses; 142 cases, or 25.4%, were hospitalized.
Key findings
- There were 9,698 febrile illnesses (31.7 per 100 person-years), with 560 dengue cases (5.8%). DENV-1 was 41.1% and DENV-2 34.5%; incidence was 2.7 in Asia-Pacific versus 1.2 in Latin America per 100 person-years. Nineteen had severe dengue/DHF and 142/560 were hospitalized.
Why this matters globally
Geographic, age and temporal variation supports adaptive dengue control linked to serotype circulation and health-system burden.
Thai researcher contribution
Mahidol University and MORU researchers contributed to a multicountry pediatric tropical-disease trial network.
Limitations to consider
This post hoc placebo-arm analysis reflects a selected trial cohort with active follow-up, not general populations. Countries were aggregated and vaccine efficacy was not evaluated here.